Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB059872 in relapsed/refractory Ewing sarcoma
NCT03514407Phase 1Terminated
- Sponsor
- Incyte
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of incb059872 in Ewing sarcoma, sponsored by Incyte. Primary endpoint: Adverse Events up to 6 months. Started Jun 2018; status: terminated.
02
Drugs
incb059872
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT03514407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514407.